---
title: "平平无奇80+分，惊呆了老铁，这是什么表演？"
date: 2023-11-22T23:37:46Z
draft: ["false"]
tags: [
  "fetched",
  "生信人"
]
categories: ["Acdemic"]
---
平平无奇80+分，惊呆了老铁，这是什么表演？ by 生信人
------
<div><section><img data-galleryid="" data-imgfileid="503742112" data-ratio="0.358974358974359" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GNVlVcMJyI8OwRb1pMKoIQjxJ432iaCttiacRDrsr49kTHnmqfbEpDVPQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1014" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GNVlVcMJyI8OwRb1pMKoIQjxJ432iaCttiacRDrsr49kTHnmqfbEpDVPQ/640?wx_fmt=png&amp;from=appmsg"></section><section><br></section><section><span>挖掘热点，看生信人！哈喽各位小伙伴好呀，近日小编在看文献时，发现一篇2023年11月9日发表在《NATURE MEDICINE》上的高分文章,初读时小编觉得该文章平平无奇，甚至产生了“马上给我样本，我也要发影响因子 82.9分”的错觉，让我们一起来看看这是什么表演吧~</span></section><section><br></section><section><strong><span></span></strong></section><section><strong><span>更贴合临床的生信挖掘</span></strong></section><section><strong><span>思路定制</span></strong></section><p><img data-imgfileid="503742143" data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjWzjS6RKQ4icmYW4QHDo4fc2kcicS80I9PupKlD2YnhxrhnbhXficRS8ZlPXpY5ACcZ4NiaoX74vKNurQ/640?wx_fmt=jpeg&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" data-type="jpeg" data-w="150" src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjWzjS6RKQ4icmYW4QHDo4fc2kcicS80I9PupKlD2YnhxrhnbhXficRS8ZlPXpY5ACcZ4NiaoX74vKNurQ/640?wx_fmt=jpeg&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1"></p><p><br></p><section><span><strong><span>为什么做这个研究？</span></strong></span></section><section><span>脑膜瘤是最常见的原发性颅内肿瘤，脑膜瘤的治疗主要局限于手术和放疗，其术后放疗的适应症存在争议，而针对脑膜瘤的全身治疗仍然是无效的或实验性的，因此有必要提出并改善脑膜瘤风险分层方法。最近的研究提出了使用DNA甲基化分析、拷贝数变异、DNA测序、RNA测序等多组学特征的脑膜瘤预后集成模型。其他癌型已提出基于靶向基因表达谱的预后模型研究，但针对脑膜瘤的研究不足。   </span><page></page></section><section><span>          </span><p><span> </span></p></section><section><span><strong><span>预后标志物模型是怎么生成的？</span></strong></span></section><section><span>a)</span><span>根据文献中的预后或生物学意义选择了脑膜瘤相关基因作为候选基因；</span></section><section><span><br></span></section><section><span>b)</span><span>基于靶向基因表达谱，以训练队列中局部无复发（LFFR）的C-index为目标终点,采用Lasso正则化Cox回归模型,进行特征选择, 在达到最大C指数的模型的1个标准误差范围内选择最优基因集（n=34，详见下表）；</span></section><section><span><br></span></section><section><span>c)</span><span>为了减少过拟合，提高校准和稳定性，并便于使用FFPE脑膜瘤样本或RNA测序以及微阵列数据的基因表达量化进行风险评分计算，进一步使用bootstrap aggregation法，以归一化和对数转换的基因计数作为输入，以训练队列0到1之间的风险评分作为目标变量，训练500个脊回归子模型。简而言之，该过程指定一个bootstrap aggregation总风险评分，定义为子模型风险评分的算术平均值；</span></section><section><span><br></span></section><section><span>d)</span><span>使用递归算法确定生存分析的基因表达风险评分阈值。在训练队列中使用最大选择的秩统计量确定一个初始阈值。以上和低于这个阈值的子集再次被最大选择的秩统计量分割，最终将样本分为高风险、中风险和低风险组。</span></section><section><span><br></span></section><section><span>表1.标志物基因集合 </span></section><section><img data-backh="713" data-backw="578" data-croporisrc="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4Gk7f7oZb6ZFNHiaqTZ0AOTvgXezVeibkpKnHfI1GBO7ncXxVclib8MnxFw/0?wx_fmt=png&amp;from=appmsg" data-cropx1="0" data-cropx2="904.9999999999999" data-cropy1="0" data-cropy2="1117.941176470588" data-galleryid="" data-imgfileid="503742134" data-ratio="1.2342541436464087" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GdpyQWDIEwWRbNI4nyQoZLY7ActfUVvIkr0DWiatDiapFAmTB8Tv2tpcQ/640?wx_fmt=jpeg" data-type="jpeg" data-w="905" src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GdpyQWDIEwWRbNI4nyQoZLY7ActfUVvIkr0DWiatDiapFAmTB8Tv2tpcQ/640?wx_fmt=jpeg"></section><section><img data-backh="773" data-backw="578" data-croporisrc="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4Gf0mK2ExhiaF92WqYIPVDjpvibdBGUU4E4vj9pMYwibaMP7jDFXl8EicCoA/0?wx_fmt=png&amp;from=appmsg" data-cropx1="0" data-cropx2="903" data-cropy1="0" data-cropy2="1207.645328719723" data-galleryid="" data-imgfileid="503742136" data-ratio="1.336655592469546" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GEc24ptSWicRVicI2svOAlXoW9un9iaSkoZtsSticJFfXo1NJXHRUbKDorw/640?wx_fmt=jpeg" data-type="jpeg" data-w="903" src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GEc24ptSWicRVicI2svOAlXoW9un9iaSkoZtsSticJFfXo1NJXHRUbKDorw/640?wx_fmt=jpeg"></section><p><img data-backh="373" data-backw="578" data-galleryid="" data-imgfileid="503742145" data-ratio="0.6449834619625138" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GY4VSyxHZZxmoept4RycaCDxcG93j5OaUWVwgQ6EKoZGm6bTqs38nDw/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="907" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GY4VSyxHZZxmoept4RycaCDxcG93j5OaUWVwgQ6EKoZGm6bTqs38nDw/640?wx_fmt=png&amp;from=appmsg"></p><p><br></p><section><span><strong><span>预后标志物模型在验证集中表现如何？</span></strong></span></section><section><span>在多中心验证队列中（n=1219），即使样本来源不同（不同实验室、冷冻或FFPE、芯片或测序），模型产生了一致的基因表达风险评分，该风险评分可很好的将不同预后的脑膜瘤患者区分。</span></section><section><span>    </span><page></page></section><p><img data-galleryid="" data-imgfileid="503742117" data-ratio="1.1149110807113543" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GY4C92RBibXeDQ8iaVe25zbeY9ojFTS2RLf6NgX7Zw6M2nH1QAg4zicicNA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="731" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GY4C92RBibXeDQ8iaVe25zbeY9ojFTS2RLf6NgX7Zw6M2nH1QAg4zicicNA/640?wx_fmt=png&amp;from=appmsg"></p><section><span>图1：验证集合中标志物的功能验证</span></section><section><span>          </span><p><span> </span></p></section><section><span><strong><span>预后标志物模型在独立测试集中表现如何？</span></strong></span></section><section><span>在独立的临床样本测试集（n=866）中，该研究的分子标志物保持了优秀的分类能力。在以局部无复发（LFFR）为生存终点时，高中低风险组的5年生存率分别为92.2% (95% CI, 88.3-96.2%), 72.6% (95% CI 67.8-77.8%)和19.4% (95% CI 13.5-28.0%)。在总生存率（OS）为生存终点时，高中低风险组的5年生存率分别为95.3% (95% CI 92.9-97.8%), 83.3% (95% CI 79.3-87.5%)和44.3% (95% CI 35.6-55.1%)。</span><page></page></section><section><span><br></span></section><section><img data-galleryid="" data-imgfileid="503742118" data-ratio="0.29259259259259257" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4Gnzmyf42qBqXtoJvRurkXbuKtDGIyvHw5o5XpWZzx8qF2BSFsS0Lb6g/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4Gnzmyf42qBqXtoJvRurkXbuKtDGIyvHw5o5XpWZzx8qF2BSFsS0Lb6g/640?wx_fmt=png&amp;from=appmsg"></section><section><span>图2：测试集合中标志物的功能验证</span></section><section><br></section><section><span><strong><span>与其他研究已有的标志物相比，该研究的标志物表现如何？</span></strong></span></section><section><span>基于配对的似然比检验来看不同分类标志物的两两组合是否提升了COX回归模型的性能。在同一个验证集合中，该研究的34个基因集合分子标志物提升了其他9个不同标志物的性能，提供了额外的预后信息，反之则不能，随着时间的推移，与其他分类标志物相比，该34基因集合分子标志物有最低的Brier错误得分，并取得最高的5年AUC值。同时作者给出了基于该标志物的列线图。</span></section><section><span><br></span></section><p><img data-galleryid="" data-imgfileid="503742119" data-ratio="0.46296296296296297" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4Gq2ibibec7Hsic3c0l6Wof0dU8M3jibMDGDVCqCKKwIFa7q7DJStcQDl58A/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4Gq2ibibec7Hsic3c0l6Wof0dU8M3jibMDGDVCqCKKwIFa7q7DJStcQDl58A/640?wx_fmt=png&amp;from=appmsg"><span> </span><span>图3：与其他标志物的比较</span></p><p><span><br></span></p><p><img data-galleryid="" data-imgfileid="503742120" data-ratio="0.30462962962962964" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GN4LTwFVlyuVTPD9FcnLib3pM6yBnvNqjOozNlm761g2TSMpt7rvUoYw/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GN4LTwFVlyuVTPD9FcnLib3pM6yBnvNqjOozNlm761g2TSMpt7rvUoYw/640?wx_fmt=png&amp;from=appmsg"></p><section><span>图4：分子标志物列线图</span></section><section><span>          </span><p><span> </span></p></section><section><span><strong><span>分子标志物可预测脑膜瘤的放疗响应</span></strong></span></section><section><span>作者将标志物预测为低风险或中风险但伴随全切手术的样本分为Favorable组（预后较好），将标志物预测为中风险且伴随次全切手术或预测为高风险的样本分为Unfavorable组（预后较差），生存分析表明，预后较差的Unfavorable组可显著获益于术后放疗，而预后较好的Favorable组则不能。</span></section><section><span>          </span><p><span> </span></p></section><section><span>RTOG 0539是一项II期多中心前瞻性试验，将来自78家机构的脑膜瘤患者纳入高中低3个临床风险组。作者将该研究的分子标志物应用于该队列，结果表明分子标志物重分类了高中低风险组（52%样本被重分类），且相比于原来的划分，该研究分子标志物提供了额外有用的预后信息，进一步证实了其稳健性和有效性。</span></section><section><span> </span><page></page></section><section><img data-galleryid="" data-imgfileid="503742121" data-ratio="0.5972222222222222" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GQDclHrYiasuvZViaP0LIye9EdCbTlB9Utxx5EvEVsu1ibhudwsHjSsXlA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjVdibQb9jzYDaU6n3qSuYg4GQDclHrYiasuvZViaP0LIye9EdCbTlB9Utxx5EvEVsu1ibhudwsHjSsXlA/640?wx_fmt=png&amp;from=appmsg"></section><section><span>图5：分子标志物可预测脑膜瘤的放疗响应</span></section><section><span>          </span><p><span> </span></p></section><section><span><strong><span>小编总结</span></strong></span></section><section><span>该研究的脑膜瘤靶向基因表达谱可识别、优化并预测脑膜瘤样本的局部复发、总生存期和是否放疗获益，与常规临床标准相比，其将高达52.0%的脑膜瘤重新分类，并可能对29.8%的患者的术后管理提供有用的预后信息。尽管该研究并没有复杂的实验套路和华丽的生信分析，看似平平无奇，但其大量的验证队列背后有稳健的验证结果支撑。</span></section><section><span><br></span></section><ul><li><section><span><strong>在训练集表现如何？好！</strong></span></section></li><li><section><span><strong><span>在验证集表现如何？也好！</span></strong></span></section></li><li><section><span><strong><span>与其他研究相比如何？更好！</span></strong></span></section></li><li><section><span><strong><span>能不能给临床带来额外的预后信息？可以！</span></strong></span><span></span></section></li></ul><section><span><br></span></section><section><span>正是这严谨稳健的思路才使该研究发了82.9的高分，小编相信该文章的思路值得各位做预后标志物的小伙伴借鉴~ </span><page></page></section><section><span><br></span></section><section><strong><span></span></strong></section><section><strong><span>更贴合临床的生信挖掘</span></strong></section><section><strong><span>思路定制</span></strong></section><p><img data-imgfileid="503742144" data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjWzjS6RKQ4icmYW4QHDo4fc2kcicS80I9PupKlD2YnhxrhnbhXficRS8ZlPXpY5ACcZ4NiaoX74vKNurQ/640?wx_fmt=jpeg&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" data-type="jpeg" data-w="150" src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjWzjS6RKQ4icmYW4QHDo4fc2kcicS80I9PupKlD2YnhxrhnbhXficRS8ZlPXpY5ACcZ4NiaoX74vKNurQ/640?wx_fmt=jpeg&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1"></p><p><br></p><section><span>参考文献：</span></section><section><span>William C Chen, et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.</span> <span>Nat Med.2023 Nov 9. doi: 10.1038/s41591-023-02586-z.</span></section><section><span><br></span></section><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section powered-by="xiumi.us"><p><strong>往期热点 </strong><span><strong><span>（点击标题跳转）</span></strong></span></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>01</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651222028&amp;idx=1&amp;sn=87b09108fde125cafe25d54c4aaf5195&amp;chksm=8b5f7763bc28fe75055c0e03ac07fe0345b20f6f379e1ac022186c72cab23d04a9537a4415b9&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='[{"href":"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651222028&amp;idx=1&amp;sn=87b09108fde125cafe25d54c4aaf5195&amp;chksm=8b5f7763bc28fe75055c0e03ac07fe0345b20f6f379e1ac022186c72cab23d04a9537a4415b9&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect"}]' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651222028&amp;idx=1&amp;sn=87b09108fde125cafe25d54c4aaf5195&amp;chksm=8b5f7763bc28fe75055c0e03ac07fe0345b20f6f379e1ac022186c72cab23d04a9537a4415b9&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>肿瘤免疫逃逸新机制</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>02</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651221974&amp;idx=1&amp;sn=573c090d0e9a59ca6302a968d4dc6891&amp;chksm=8b5f68b9bc28e1afef3bf3e7ae936ff44033760a468f414f647a7ebfc0c753f0f0bd5d838eb0&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='[{"href":"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651221974&amp;idx=1&amp;sn=573c090d0e9a59ca6302a968d4dc6891&amp;chksm=8b5f68b9bc28e1afef3bf3e7ae936ff44033760a468f414f647a7ebfc0c753f0f0bd5d838eb0&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect"}]' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651221974&amp;idx=1&amp;sn=573c090d0e9a59ca6302a968d4dc6891&amp;chksm=8b5f68b9bc28e1afef3bf3e7ae936ff44033760a468f414f647a7ebfc0c753f0f0bd5d838eb0&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>孟德尔随机化</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>03</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651221366&amp;idx=1&amp;sn=b0d15c3558eb47a25c27f0c6d822cce6&amp;chksm=8b5f6a19bc28e30f1a6b6de5e94de4a6dc94f2023f4c84ab7cb12c5142945f4a5c74a7faa13b&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='[{"href":"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651221366&amp;idx=1&amp;sn=b0d15c3558eb47a25c27f0c6d822cce6&amp;chksm=8b5f6a19bc28e30f1a6b6de5e94de4a6dc94f2023f4c84ab7cb12c5142945f4a5c74a7faa13b&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect"}]' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651221366&amp;idx=1&amp;sn=b0d15c3558eb47a25c27f0c6d822cce6&amp;chksm=8b5f6a19bc28e30f1a6b6de5e94de4a6dc94f2023f4c84ab7cb12c5142945f4a5c74a7faa13b&amp;token=2143414347&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>生信+实验结合</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>04</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='[{"href":"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"}]' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>单细胞空间转录组</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>05</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" formlinkparm='[{"href":"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect"}]' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>肿瘤相关巨噬细胞（TAM）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>06</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" formlinkparm='[{"href":"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect"}]' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>细胞死亡</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>07</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='[{"href":"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"}]' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>耐药</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><span><strong><span>文章转载请联系 | 15510012760（微信）</span></strong></span></p><p><span>    </span><p><span> </span></p><span>    </span></p></section></section></section></section><section><page></page></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/xakZdDNFqun0gFy8fBcglw",target="_blank" rel="noopener noreferrer">原文链接</a>
